Gastroesophageal Cancer Clinical Trials

22 recruitingLast updated: June 17, 2026

There are 22 actively recruiting gastroesophageal cancer clinical trials across 19 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3. Top locations include Nashville, Tennessee, United States, Houston, Texas, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Gastroesophageal Cancer Trials at a Glance

22 actively recruiting trials for gastroesophageal cancer are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Nashville, Houston, and New York. Lead sponsors running gastroesophageal cancer studies include H. Lee Moffitt Cancer Center and Research Institute, BeiGene, and Barbara Malene Fischer.

Browse gastroesophageal cancer trials by phase

Treatments under study

About Gastroesophageal Cancer Clinical Trials

Looking for clinical trials for Gastroesophageal Cancer? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastroesophageal Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastroesophageal Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 2

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Breast CancerColorectal, CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals200 enrolled28 locationsNCT06695845
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting
Phase 1

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Gastric Adenocarcinoma+10 more
IDEAYA Biosciences260 enrolled12 locationsNCT07277413
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled53 locationsNCT06253871
Recruiting
Phase 2

BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer

Gastroesophageal Cancer (GC)Pancreatic Cancer, Adult
Barbara Malene Fischer90 enrolled1 locationNCT07629609
Recruiting
Phase 1

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

Gastric (Stomach) CancerGastroesophageal CancerPancreatic Ductal Adenocarcinoma (mPDAC)
Dong-A ST Co., Ltd.51 enrolled3 locationsNCT07481357
Recruiting
Phase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Breast CancerEsophageal CancerPancreatic Cancer+13 more
ModeX Therapeutics, An OPKO Health Company285 enrolled6 locationsNCT06239194
Recruiting
Not Applicable

The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)

Gastroesophageal CancerIncurable Disease
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)196 enrolled22 locationsNCT06138223
Recruiting
Not Applicable

Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer

Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute80 enrolled2 locationsNCT06497569
Recruiting
Phase 2

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Gastric CancerGastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute36 enrolled1 locationNCT06109467
Recruiting

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Gastroesophageal CancerGastrostomyGastric
M.D. Anderson Cancer Center20 enrolled4 locationsNCT05205343
Recruiting
Phase 2

Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer

Gastric CancerGastroesophageal Cancer
Shanghai Zhongshan Hospital84 enrolled2 locationsNCT06468280
Recruiting

Sample Collection for Ongoing Research and Product Evaluation Study

Breast CancerLiver CancerPancreatic Cancer+9 more
Natera, Inc.9,600 enrolled1 locationNCT07318051
Recruiting
Phase 2

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Gastric CancerGastroesophageal CancerAdenocarcinoma
Harry H Yoon58 enrolled2 locationsNCT04069273
Recruiting

Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer

SarcopeniaQuality of Life (QOL)Chemotherapy+6 more
Karolinska Institutet130 enrolled1 locationNCT06687291
Recruiting
Phase 2

PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer

Esophageal CancerGastroesophageal CancerOesophageal Cancer
Medical College of Wisconsin50 enrolled1 locationNCT06906887
Recruiting
Phase 2Phase 3

Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer

Gastric CancerChemotherapyGastroesophageal Junction Adenocarcinoma+13 more
Ukrainian Society of Clinical Oncology150 enrolled2 locationsNCT06028737
Recruiting
Phase 2

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

Non-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaCarcinoma, Hepatocellular+3 more
National University Hospital, Singapore360 enrolled1 locationNCT06422403
Recruiting
Not Applicable

Anti-Migration System for Anti-reflux Oeso-gastric Stent (ANTIMIG)

Gastroesophageal CancerStent Migration
Société Française d'Endoscopie Digestive180 enrolled1 locationNCT05431738